Category: Investment, Biotech, Pharma

Biotech stocks News; BioSante (NasdaqGM: BPAX) Shares on the Upswing While Cell Therapeutics Lag

The Paragon Report Provides Equity Research on BioSante Pharmaceuticals & Cell Therapeutics

Visit this company: www.biosantepharma.com

NEW YORK, NY - February 15, 2012 (Investorideas.com Newswire) Biotech stocks have been on an impressive run in 2012 -- handedly outperforming the Dow Jones industrial average year-to-date. The iShares Nasdaq Biotechnology Index Fund -- which contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals -- is up more than 16 percent this year. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on BioSante Pharmaceuticals Inc. (NASDAQ: BPAX) and Cell Therapeutics, Inc. (NASDAQ: CTIC). Access to the full company reports can be found at:

www.paragonreport.com/BPAX www.paragonreport.com/CTIC

Earlier this month The Food and Drug Administration's (FDA) much anticipated guidelines for the sale of lower-cost versions of biotechnology drugs required studies showing that the generic copies are "highly similar" to the originals, but there are several ways that might be proven. According to market analysis firm Datamonitor, the worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as more than 30 branded biologics with sales of $51 billion lose patent exclusivity.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. Shares of the company were hammered in late January after the company voluntarily withdrawn its New Drug Application for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy. Shares of Cell Therapeutics are lagging the industry this year and are down more than 7 percent in 2012.

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, develops products for female sexual health and oncology. Its lead products include LibiGel (transdermal testosterone gel) for the treatment of female sexual dysfunction. Earlier this month the company announced in a statement that the independent Data Monitoring Committee has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. Shares of BPAX are up more than 50 percent year-to-date.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured biotech/pharma stock on Investorideas.com

Request news, updates and trading alerts on BPAX and other stocks http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure: Investorideas.com is paid by BPAX to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (six thousand five hundred per three months of publishing)

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  

Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  

Source: Investorideas.com, BioSante, Investorideas.com

800 665 0411 cvanzant@investorideas.com

More Info:

This news is published on the Investorideas.com Newswire and its syndicated partner network

News now!

Get Investorideas.com investor news and stock alerts
Free Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer: The following news is paid for and /or published as information only for our readers.

Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp

Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

TOP